ICMR to launch Covid vaccine by Aug 15


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ ICMR to launch Covid vaccine by Aug 15
No vaccine has yet been approved for commercial use against COVID-19 in India

New Delhi: The first made-in-India coronavirus vaccine may be launched by August 15, with the Indian Council of Medical Research (ICMR) fast-tracking efforts to develop "Covaxin" in partnership with Bharat Biotech International Limited. A dozen institutes have been selected for clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine), the government's top medical research body has said.

The institutes have been asked by the ICMR to step up clinical trials as it is a "priority project" monitored at the topmost level of the government.

"The vaccine is derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the pre-clinical as well as clinical development of this vaccine," the ICMR said in a letter to the institutes.

The ICMR talked about plans to launch the vaccine for public health use by August 15, Independence Day. Experts have questioned the deadline, since the clinical trial is yet to begin.

"It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials," said the research body.

The final outcome will depend on the cooperation of all clinical trial sites involved in this project, the ICMR told the institutes, advising them to speed up approvals related to clinical trials and ensure that subjects are enrolled starting this week.

"Non-compliance will be viewed very seriously. Therefore, you are advised to treat this project on highest priority and meet the given timelines without any lapse," said ICMR's letter.

Bharti Biotech's application for clinical trial, accessed by NDTV, reveals that the estimated duration of the trial is one year and three months. The sample size of the study is 1,125 people between 12 and 65 years. Out of the 12 institutes picked BY ICMR, seven are yet to establish an "Ethics Committee" to oversee the trial.

"How can ICMR say that the vaccine will be launched for public use by August 15? How can the clinical trial be completed in just one month for a vaccine," wondered Amulya Nidhi of Jan Swasthya Abhiyan, a network of organisations working on public health.

While ICMR has refused to comment on its letter, Satyajit Mohapatra, who is in charge of the clinical trial in SRM Hospital and Research Centre, Tamil Nadu, told NDTV: "ICMR has given a timeframe for completion of Phase 1 of the trial by August. Phase 2 of the study will start after completion of Phase 1, followed by Phase 3."

The Phase 1 is planned for completion in 28 days, which would meet the August 15 deadline. It is not clear how the vaccine can be made available for public use with just the results of the first phase.

Worldwide, scientists are racing to produce a vaccine for the deadly virus that has infected over 10 million, including 600,000 in India, and caused more than 500,000 deaths.

No vaccine has yet been approved for commercial use against COVID-19. More than a dozen possible vaccines from over 100 being developed globally are being tested on humans. Some have shown potential in early-stage trials.

Tags : #ICMR #Covaxine #BharatBiotech #CovidVaccine #CovidVaccineIndia #JanSwasthyaAbhiyan #Sars-Cov-2 #NationalInstituteofVirology #Pune

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026